+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma



Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma



International Journal of Cancer 119(1): 17-27



Human malignant mesothelioma (HMM) is resistant to many anticancer drugs, including doxorubicin. Mevastatin and simvastatin, 2 inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, potentiated the intracellular accumulation and the cytotoxicity of doxorubicin in HMM cells constitutively expressing P-glycoprotein and multidrug resistance-associated protein 3. This effect of statins was nitric oxide (NO)-dependent, since it was reverted by either an NO synthase inhibitor or an NO scavenging system. The NO synthase up-regulation in HMM and other cells is known to be associated with the activation of the transcription factor NF-kappaB: in HMM cells statins increased the NF-kappaB translocation into the nucleus, decreased the level of the NF-kappaB inhibitor IkBalpha and increased the phosphorylation/activation of IkB kinase alpha (IKKalpha). IKKalpha is under the negative control exerted by RhoA in its prenylated (active) form: incubation of HMM cells with statins lowered the amount of active RhoA and the level of Rho-associated kinase activity. All statins' effects were reverted by mevalonic acid, thus suggesting that they were mediated by the inhibition of HMGCoA reductase and were likely to be subsequent to the reduced availability of precursor molecules for RhoA prenylation. Both the Rho kinase inhibitor Y27632 and the RhoA inhibitor toxin B (from Clostridium difficile) mimicked the statins' effects, enhancing doxorubicin accumulation, NO synthesis and IKKalpha phosphorylation and decreasing the amount of IkBalpha in HMM cells. Simvastatin, Y27632 and toxin B elicited tyrosine nitration in the P-glycoprotein, thus providing a likely mechanism by which NO reverts the doxorubicin resistance in HMM cells.

(PDF emailed within 0-6 h: $19.90)

Accession: 012581672

Download citation: RISBibTeXText

PMID: 16450390

DOI: 10.1002/ijc.21832


Related references

Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. British Journal of Cancer 83(7): 880-886, 2000

Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines. International Journal of Cancer 75(5): 757-761, 1998

Multicellular resistance to doxorubicin is attenuated by nitric oxide mimetics. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1304, July, 2003

Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide. Vascular Pharmacology 63(2): 63-70, 2015

Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology (Oxford) 39(2): 179-186, August, 2001

Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research 14(7-8): 381-386, 2004

Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Research and Treatment 96(2): 169-176, 2005

Induction of transient resistance to doxorubicin in tumor cells exposed to nitric oxide secreted by activated macrophages. Proceedings of the American Association for Cancer Research Annual Meeting 33: 423, 1992

Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochemical Journal 440(2): 175-183, 2012

Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells. Bioorganic Chemistry 64: 51-58, 2017

Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Research 65(2): 516-525, 2005

Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. Lung Cancer 38(2): 159-162, 2002

Treatment of human breast cancer cells with nitric oxide mimetics prevents acquisition of hypoxia-induced resistance to doxorubicin. Proceedings of the American Association for Cancer Research Annual Meeting 42: 814-815, March, 2001

Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Seminars in Oncology 29(1): 62-69, 2002